Safety and efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients with preexisting antinuclear antibodies: a retrospective cohort study

BACKGROUND: Antinuclear antibodies (ANAs) predicting the safety and efficacy of patients with advanced non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs) are still a matter of debate considering previous studies showed quite different results based on different ANA c...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Dongming, Shi, Yuequan, Liu, Xiaoyan, Liu, Jia, Xu, Yan, Zhao, Jing, Zhong, Wei, Käsmann, Lukas, Hakozaki, Taiki, Provencio, Mariano, Horita, Nobuyuki, Fukuda, Nobuhiko, Chen, Minjiang, Wang, Mengzhao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359963/
https://www.ncbi.nlm.nih.gov/pubmed/35958331
http://dx.doi.org/10.21037/tlcr-22-464

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359963/
https://www.ncbi.nlm.nih.gov/pubmed/35958331
http://dx.doi.org/10.21037/tlcr-22-464

Ejemplares similares